Genomics and functional dissection of fetal brain abnormalities using a prenatal cohort
Project Number5R01HD105868-04
Contact PI/Project LeaderVORA, NEETA L
Awardee OrganizationUNIV OF NORTH CAROLINA CHAPEL HILL
Description
Abstract Text
ABSTRACT
Fetal brain abnormalities (FBA) are one of the most common prenatal sonographic abnormality detected and
account for ~20% of birth defects posing a substantial burden on the health care system. FBA can be isolated
or syndromic and have vast phenotypic heterogeneity. The paired approach of prenatal diagnosis using
ultrasound to characterize aberrant phenotypes with genetic analysis to determine causal lesions has improved
the ability to accurately counsel families about diagnosis, prognosis, and recurrence risk. Recently, prenatal
exome sequencing (ES) has been applied in cases of lethal or multiple fetal abnormalities to determine a
molecular diagnosis that otherwise could not be identified with traditional testing. Our group and others using ES
have shown a diagnostic rate of 23.6% in cases of multiple fetal abnormalities, but only 2.6% in isolated FBA
abnormalities, indicating a need to improve diagnostic capabilities for FBA. We posit that the overabundance of
unresolved fetal cases is due to a gap in our understanding of the repertoire of genotypes underlying prenatal
FBA and limitations of population genetics to establish causality of rare variants in novel candidate genes. Our
team who is at the forefront of prenatal genetic diagnostics and in vivo zebrafish modeling of human disease will
overcome the current challenges of diagnosing prenatal FBA. We will intersect exome- and genome-wide
variation with a relevant model system (zebrafish).
We hypothesize that we will 1) generate initial discoveries
directly relevant to human brain development by modeling novel candidate FBA genes in zebrafish; and 2)
improve prenatal diagnosis for FBA using whole genome sequencing (WGS) and deep phenotyping. We will: 1.
Perform bioinformatic analysis of 200+ clinically ascertained fetuses with FBA and their parents using a tiered
filtering strategy on already available parent-fetus trio exome data 2. Perform WGS on 114 prospectively enrolled
fetuses and their parents paired with comprehensive prenatal and postnatal phenotypic data to further
characterize genotype/phenotype of FBA; 3. Establish relevance of candidate genes to FBA development and
determine variant pathogenicity using genome-editing and phenotyping tools in zebrafish. Our work will expand
the understanding of molecular processes governing human brain development, establish a clinical-research
hybrid platform readily applicable to FBA and other anatomical defects detectable by fetal imaging, build an
animal model of aberrant FBA development with potential for future use in therapeutic target identification. Our
immediate results will improve counseling/management of prenatally diagnosed FBA and lead to future work to
develop novel therapeutic and preventative strategies for FBA.
Public Health Relevance Statement
PROJECT NARRATIVE
Diagnostic tools, such as prenatal ultrasound and prenatal gene sequencing, have the capability to increase our
understanding of fetal brain abnormalities (FBA). By intersecting human prenatal sequencing, bioinformatics
filters to identify novel candidate genes, and functional modeling in an animal model, we aim to identify novel
candidate genes specific to FBA; additionally, we will perform whole genome sequencing on a prospective cohort
with FBA to increase our understanding of diagnostic yield and genotypes/phenotypes in a well characterized
cohort. Our findings will shed light on the molecular underpinnings of human brain development and has the
potential to improve pre- and postnatal counseling/management, and lead to novel preventive and therapeutic
strategies that can be applied in the perinatal period.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
608195277
UEI
D3LHU66KBLD5
Project Start Date
12-August-2021
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$633,886
Direct Costs
$460,786
Indirect Costs
$173,100
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$633,886
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01HD105868-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HD105868-04
Patents
No Patents information available for 5R01HD105868-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HD105868-04
Clinical Studies
No Clinical Studies information available for 5R01HD105868-04
News and More
Related News Releases
No news release information available for 5R01HD105868-04
History
No Historical information available for 5R01HD105868-04
Similar Projects
No Similar Projects information available for 5R01HD105868-04